Gilead (Kite) Partners with COTA to Accelerate Clinical Development Using Real-World Data
Here is a brief preview of this blast: On Tuesday, March 16, Gilead (Kite) announced a collaboration with COTA (press release), a real-world data (RWD) analytics company, to accelerate Gilead’s oncology CAR-T pipeline. Of note, COTA could provide valuable insights into clinical trial design and perhaps future therapeutic applications. Below, Celltelligence provides insights on how Gilead (Kite) could leverage COTA’s data to strategically accelerate promising clinical assets, as well as similar RWD partnerships for BMS, Novartis, and Tmunity.